155 related articles for article (PubMed ID: 15989496)
41. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
42. The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.
McLaughlin J; Houghton LA
Expert Opin Drug Saf; 2006 Mar; 5(2):313-27. PubMed ID: 16503751
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
Tamaoki S; Yamauchi Y; Nakano Y; Sakano S; Asagarasu A; Sato M
J Pharmacol Exp Ther; 2007 Sep; 322(3):1315-23. PubMed ID: 17540858
[TBL] [Abstract][Full Text] [Related]
44. Review of tegaserod in the treatment of irritable bowel syndrome.
Patel S; Berrada D; Lembo A
Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
[TBL] [Abstract][Full Text] [Related]
45. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
46. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
Cole P; Rabasseda X
Drugs Today (Barc); 2004 Dec; 40(12):1013-30. PubMed ID: 15645012
[TBL] [Abstract][Full Text] [Related]
47. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
48. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
Atkinson W; Lockhart S; Whorwell PJ; Keevil B; Houghton LA
Gastroenterology; 2006 Jan; 130(1):34-43. PubMed ID: 16401466
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
50. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
51. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
Kerckhoffs AP; Ter Linde JJ; Akkermans LM; Samsom M
Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
[TBL] [Abstract][Full Text] [Related]
52. 5-Hydroxytryptamine and functional bowel disorders.
Sanger GJ
Neurogastroenterol Motil; 1996 Dec; 8(4):319-31. PubMed ID: 8959736
[TBL] [Abstract][Full Text] [Related]
53. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
[TBL] [Abstract][Full Text] [Related]
54. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
Andresen V; Hollerbach S
Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
[TBL] [Abstract][Full Text] [Related]
55. Treatment options in irritable bowel syndrome.
Farthing MJ
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
[TBL] [Abstract][Full Text] [Related]
56. Alterations in serotonin metabolism in the irritable bowel syndrome.
Thijssen AY; Mujagic Z; Jonkers DM; Ludidi S; Keszthelyi D; Hesselink MA; Clemens CH; Conchillo JM; Kruimel JW; Masclee AA
Aliment Pharmacol Ther; 2016 Jan; 43(2):272-82. PubMed ID: 26538292
[TBL] [Abstract][Full Text] [Related]
57. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
Spiller R
Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
[TBL] [Abstract][Full Text] [Related]
59. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.
Heading R; Bardhan K; Hollerbach S; Lanas A; Fisher G
Aliment Pharmacol Ther; 2006 Jul; 24(2):207-36. PubMed ID: 16842449
[TBL] [Abstract][Full Text] [Related]
60. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
